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Abstract
The biochemistry of the mitogen activated protein kinases ERK, JNK, and p38 have been studied
in prostate physiology in an attempt to elucidate novel mechanisms and pathways for the treatment
of prostatic disease. We reviewed articles examining mitogen-activated protein kinases using
prostate tissue or cell lines. As with other tissue types, these signaling modules are links/
transmitters for important pathways in prostate cells that can result in cellular survival or
apoptosis. While the activation of the ERK pathway appears to primarily result in survival, the roles
of JNK and p38 are less clear. Manipulation of these pathways could have important implications
for the treatment of prostate cancer and benign prostatic hypertrophy.
Background
Signal transduction via mitogen activated protein (MAP)
kinases plays a key role in a variety of cellular responses,
including proliferation, differentiation, and cell death.
MAP kinases have provided a focal point for remarkably
rapid advances in our understanding of the control of cel-
lular events by growth factors and stresses. Since their ini-
tial discovery in yeast, over a dozen MAP kinase families
have been identified of these highly genetically conserved
proteins. MAP kinase signal transduction pathways have
not been studied in great detail in the prostate; however
over one hundred publications describing the effects of
various manipulations, including growth factors, chemi-
cal modifiers and androgens on prostatic cells have been
described in the literature. Despite these studies, the struc-
ture and function of the MAP kinase pathways in prostate
are far from clearly understood.
Diseases of the prostate are a tremendous source of mor-
bidity and mortality in aging males. Benign enlargement
of the prostate gland is a significant source of discomfort
and prostate cancer is the second leading cause of cancer
related deaths in males. Most of the prostate cancer deaths
result from emergence of an androgen resistant pheno-
type of prostate cancer. Unfortunately, treatment options
for these androgen resistant prostate cancer patients are
few and generally ineffective. These facts underline the
need to develop new therapies that will improve outlook
for hormone-independent prostate cancer. Several lines of
evidence suggest a role for MAP kinase signal transduction
pathways in prostate cancer. Here we provide a
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comprehensive review of studies specifically using pros-
tate tissue or cell lines. Admittedly, many more publica-
tions may have examined some aspect of MAPKs, but we
focused on abstracts including MAPK, ERK, JNK, or p38.
The three major MAP kinase (MAPK) pathways include
the extracellular-signal regulated kinase (ERK, also known
as p42/44 MAP kinase), c-jun  N-terminal kinase (JNK,
also known as stress activated protein kinase-1 (SAPK1))
and p38 MAPK (also known as SAPK2/RK). In general,
ERK1 and ERK2 are key transducers of proliferation sig-
nals and are often activated by mitogens. In contrast,
SAPKs/JNKs and p38 are poorly activated by mitogens but
strongly activated by cellular stress inducers. After activa-
tion, these cytosolic proteins translocate to the nucleus to
activate numerous proteins and/or transcription factors.
Each MAPK cascade consists of a core MAPK module,
which has no less than three enzymes activated in series:
1) a MAPK, 2) an immediate upstream kinase (Known as
Mitogen Activated Protein Kinase Kinase or MAPKK), and
3) an additional kinase upstream of the MAPKK (Known
as Mitogen Activated Protein Kinase Kinase Kinase or
MAPKKK). These regulatory cascades not only convey
information to the target effectors, but also coordinate
incoming information from parallel signaling pathways.
These mechanisms allow for signal amplification and gen-
erate a threshold subject to multiple activation cascades.
Then there are elements upstream of the core module. The
interactions between MAP kinase and its immediate
upstream kinase (MAPKK) are highly specific: for
instance, p42/p44 MAP kinases are phosphorylated solely
by MAP/ERK kinase (MEK) 1 and 2; p38 MAP kinase is
selectively activated by MAP kinase kinases (MKK) 3 and
6, while JNK is activated by MKK7 and MKK4 in most con-
ditions, however MKK4 can sometimes activate p38 MAP
kinase when over expressed. The specificity is less clearly
defined for elements upstream of the MAPKK modular
level. For instance MAPKKK are highly promiscuous and
can interact with and activate a number of down stream
components. Similarly, signaling cross talk in the trans-
mission levels between the mitogen/stress activator and
the core MAPK module understandably adds more com-
plexity to subtle differences in response despite equivalent
activation. The specificity upstream of the core module
may be regulated by additional components like scaffold
proteins that help bring the specific components of the
MAPK machinery together or keep various components
from interacting with each other. A simplistic view of the
MAP kinase signal transduction is presented in Figure 1.
p42/p44 MAP kinase and the prostate
Expression and activation of p42/p44 MAP kinase in tissue
In normal noncancerous tissue from radical prostatec-
tomy specimens, immunohistochemistry localizes ERK to
the cytoplasm of most cells of the prostate including the
epithelial, basal, and stromal cells [1,2]. Despite the abun-
dance of ERK it does not appear to be active in the epithe-
lial layer of normal prostatic tissue, but up to 80% of cells
in the stroma and basal layers will stain positively for
phosphorylated ERK (p-ERK) within the nucleus [3].
Gioeli et al also described p-ERK staining in normal pros-
tate tissue adjacent to areas of prostate cancer and found
that ERK activation was directly related to poor histologic/
prognostic features [4].
Nearly all studies involving this pathway have been exam-
ined using prostate cancer cell lines. There are 40 prostate
cell lines available in the ATCC catalog of both normal
and cancerous tissue. The most commonly used cell lines
are the androgen sensitive LNCaP cells, isolated from a
cancerous supraclavicular lymph node, and the androgen
insensitive cell lines DU145 and PC3, derived from brain
and bone metastasis respectively. Of note, DU145 cell
lines have basal ERK activation from paracrine/autocrine
factors that is not demonstrated in other cell lines. Karyo-
types have been described for these lines and more
recently for a variety of the other cells lines available [5].
Studies of kinase activation in normal prostate tissue cell
lines are remarkably absent from the literature.
The most well studied ligands/mitogens in prostatic cells
are epidermal-derived growth factor (EGF), transforming
growth factor (TGF)-α, and insulin-like growth factor
(IGF). The mechanism of action of these proteins is well
described in many reviews [6-8]. Generally, the ligands
interact with a membrane receptor and transmit a signal
to a cytosolic tyrosine kinase. EGF and TGF-α share about
35% sequence homology and bind to the same receptor,
the epidermal growth factor receptor (EGFR). The ERK
module appears to be a primary signal relay as inhibition
of this activation prevents cellular proliferation induced
by EGF as well as numerous other mitogens, which oper-
ate by transactivating the EGF receptor [9]. There are
numerous effectors of the ERK pathway in prostate cancer
cells and these are described in Table 1 and 2. These
stresses and agents are of considerable interest in that they
are potential manipulators of this cascade.
Androgenic manipulation has been a mainstay of prostate
cancer treatment for over 60 years, but the clinically chal-
lenging cancers will grow aggressively in the absence of
androgens. Of considerable interest in prostate physiol-
ogy is the relationship between androgens, the androgen
receptor, and the MAP kinase cascade. The effect of the
potent androgen dihydrotestosterone (DHT) is still
unclear as it activated ERK in one study but not in numer-
ous others with LNCaP cells [9-11]. Regardless of the
effect on ERK, the contribution of MAPK to cellular prolif-
eration due to DHT appears to be small relative to otherCell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/5
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pathways. With the apparent poor evidence suggesting
direct androgen stimulation of ERK, the focus has been
redirected on Interleukin (IL) -6 and the communication
links between this important cytokine and the androgen
receptor.
The interaction of IL-6 with the MAPK pathways is of par-
ticular interest for this is suspected to be a major autocrine
factor in the progression of hormone refractory prostate
cancer. There is an excellent review of the intracellular
activities initiated by IL-6 [12]. IL-6 appears to be able to
transactivate the androgen receptor in the absence of
androgens at the N-terminal domain as well as increase
the mRNA for the androgen receptor. Activation of andro-
gen receptor by IL-6 involves the ERK pathway among
others [13,14]. ERK also appears to be involved in the
phosphorylation of steroid receptor co-activator (SRC) -1,
which binds to the androgen receptor [15]. LNCaP cells
are also sensitive to IL-6 as an interesting study demon-
strated that IL-6 exposed tumors injected into nude mice
demonstrated an abrogation of proteins involved in cell
cycle control. Inhibition with PD98059 was able to retard
the cancer growth of these IL-6 exposed cells [16]. Our
preliminary studies demonstrate that IL-6 expression by
PC3, a line of hormone refractory prostate cancer cells is
in part regulated by ERK signal transduction pathway
(Koul et al in press]
EGF is extremely important in the study of cancer. Medi-
cations that interact with this receptor are regularly used
in breast malignancies and they are being examined in
many other tumor types. Interference with the EGFR
either through prevention of ligand binding, disruption of
surface expression, or prohibition of cytosolic protein
interaction can inhibit ERK activation. Multiple studies
have demonstrated interaction with EGFR by one of the
Schematic representation of MAP kinse Signal transduction Pathways Figure 1
Schematic representation of MAP kinse Signal transduction Pathways.Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/5
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aforementioned means can affect prostate cancer cell
growth and invasion in PC3 and DU145 cells [17]. Tyr-
phostin AG825 and ZM252868 are two promising mole-
cules that act in this fashion [18,19]. G protein coupled
receptors appeared to be very important in communicat-
ing with the EGF receptor in prostate physiology [20]. G
proteins can transactivate the EGFR through a variety of
means, which include cytosolic protein activation and
metallomatrix protein pro-ligand cleavage. Numerous
physiologic molecules normally activate this pathway
including lysophosphatidic acid, bombesin, adenosine
triphosphate (ATP), and 5-HETE [21-26]. A number of
other metabolites appear to operate specifically via the
metallomatrix protein pathway and these pathways can
be inhibited with methyl selenium molecules [27].
Protein signaling
Numerous cytosolic proteins are involved in the intracel-
lular events leading to ERK activation. Among these
important molecules are ras, PTEN, ID-1, DOC-2/DAB2,
Protein kinase C (PKC) epsilon and some of the integrin
subtypes [28-32]. One of the intracellular proteins that
transmit signals from the EGF receptor to the modular
MAPK pathway is ras. Isoprenylation allows ras  to
approach the membrane, a requirement for interaction
with the EGFR. This chemical reaction is facilitated by
HMG-COA reductase and the statin-family of drugs and
phenyl acetate can inhibit this process [33,34].
The first part of the modular MAPK cascade resulting in
ERK activation is the Raf molecule, which includes three
isoforms, Raf-1, RafA, and RafB. These molecules have not
been extensively studied with regards to prostate cancer.
One interesting study used the LNCaP cell line transfected
with a constitutively active form of Raf-1, which increased
ERK activity and decreased plating and cloning efficiency
[35]. This observation is contrary to other studies by sug-
gesting that ERK activation may have tumor suppressor
effects or perhaps chronic high level activation may have
different responses. Raf kinase inhibitor protein (RKIP) is
a protein that inhibits activation of MEK/ERK and appears
to be a metastasis suppressor gene. Fu et al investigated
clinical samples of local and metastatic prostate tissue and
demonstrated immunohistochemical presence of RKIP
was inversely related to histological grade. Additionally,
no RKIP antigen was found in metastatic deposits. These
Table 1: p42/p44 MAP kinase Activating agents in Prostatic cells
Agent Cell line Cell effect Ref
Endogenous
Epidermal-derived growth factor (EGF) LNCaP, DU145, PC3 Proliferation 8,9,89,90
Transforming growth factor (TGF)-α PC3 Proliferation 91
Insulin-like growth factor (IGF) LNCaP, DU145, LAPC-4, PC3 Proliferation 89,92
Fibroblast-derived growth factors (FGF) LNCaP Growth 93
Interluekin (IL)-6 LNCaP ? 12,94
Neu differentiation factor (NDF)/Heregulin LNCaP ? 81
Lysophosphatidic acid (LPA) DU145, PC3 Proliferation 9,95
Bombesin DU145, PC3 Proliferation 22,95
Bradykinin PC3 Proliferation 96
Epinephrine LNCaP NE diff (?) 94
Adenosine triphosphate tumor spheroids ? 97
Vitamin D LNCaP ? 47
5-HETE PC3 Proliferation 26
13-(S)-HODE PC3 ? 38
Nitric oxide (NO) LNCaP, PC3 ? 37
Androgens
Testosterone LNCaP Survival 50
Dihydrotestosterone (DHT)* Primary prostate stromal, 
LNCaP
?1 0
Hydroxyflutamide (antiandrogen) DU145, PC3AR2, CWR22 ? 98
Exogenous
Heat PC3 ? 33
Hypoxia LNCaP, PC3 ? 37
ionizing radiation DU145 Survival 53
Resveratrol (stilbene) DU145 Apoptosis 45
Phenylethyl isothiocyanate (PEITC) PC3 Apoptosis 46
DDT (pesticide) LNCaP ? 99
1 *not supported by other studies.Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/5
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investigators also demonstrated no effect of this protein
on tumor growth, but in vitro and in vivo evidence of
decreased metastasis [36]. These results support results
from our lab that show inhibition of p42/p44 MAP kinase
affects in vitro clonogenic potential in PC3 cells. Taken
together these results suggest that inhibition of this path-
way may be effective in preventing metastatic deposits,
but not gross tumor growth.
Results of ERK activation
Immediately downstream of ERK, numerous proteins are
activated that generally contribute to invasive potential,
cell proliferation/differentiation, or survival in adverse
environments. The continuation of vascular endothelial
growth factor (VEGF) secretion despite cell contact
appears to be regulated by ERK in LNCaP cell lines with
inactivated focal adhesion kinases (FAK) via a ras-inde-
pendent pathway [37]. Peroxisome proliferators-activated
receptor (PPAR) Gamma appears to be an important ele-
ment in regulation of proliferation and differentiation of
PC3 cells. This protein is phosphorylated (inactivated) by
ERK activation, thus unshackling cell growth from this
control [38]. Prostate specific antigen (PSA) promotion is
an ERK sensitive phenomenon in androgen independent
conditions and this may explain the continuing rise in
PSA in hormone refractory prostate cancer [39]. A study
using PC3 cells showed that prostaglandin E2 was able to
promote cell survival in oxygen poor environments by
increasing hypoxia inducible factor-1α (HIF-1alpha) pro-
tein levels via a pathway inhibited by PD98059 [40].
Another study examined fibroblast-derived growth factor
(FGF)-1 stimulation in LNCaP cells and this stimulation
resulted in an increase in promatrilysin via ERK/STAT3
pathways [41]. This enzyme is associated with increased
prostate cell invasion. Radiation exposed DU145 cells had
increased production of DNA repair proteins, XRCC1 and
ERCC1 by ERK related mechanisms [42]. Additionally,
ERK may be involved in the expression of integrins as
UO126 was able to inhibit binding to the promoter
region of the alpha 6-integrin gene in only PC3 cells [43].
Androgen-sensitive LNCaP cells grown in an androgen
deprived environment can develop neuroendocrine phe-
notypes in certain clones. ERK is constitutively activated
in these cells via an elevated level of receptor-type protein-
tyrosine phosphatase alpha. Inhibition of ERK with
PD98059 prevents neuroendocrine differentiation and
the increased level of neuron-specific enolase [44].
The effect of phospho-ERK on prostate cancer cells can
either be one of reducing apoptosis or more commonly
one of induction of cellular proliferation. Certainly, the
relative activation of the ERK isoforms can have variable
cellular effects, but this has not been evaluated in detail in
prostate cancer. A few studies have demonstrated ERK
dependent apoptosis in prostate cancer cells. Resveratrol
in DU145 cells and phenylethyl isothiocyanate in PC3
cells both produce rapid phosphorylation of ERK and
cause apoptosis [45,46]. Other MAPK pathways do not
appear necessary for this apoptotic event even though
they may be activated. A few other studies view more indi-
rect evidence that ERK activation can inhibit proliferation
or other similar effects. In particular, vitamin D is able to
activate ERK and also has inhibitory effects on cellular
proliferation, but a causal relationship was not estab-
lished [47]. Also, bryostatin 1 was able to induce apopto-
sis and Raf1/ERK activation in LNCaP cells that over
express PKCα [48].
There is a substantial body of evidence supporting ERK
and its effects on survival and proliferation. Both 13-(S)-
HODE and 5-HETE cause PC3 cells to grow most likely by
the ERK pathway [26,38]. Also, inhibition of the ERK
pathway has resulted in either decreased survival or
increased apoptosis in cancer cell lines. In particular, 4-
HPR in several studies documented apoptotic effects in
multiple prostate cancer cell lines and these effects were
increased with the inhibition of the ERK pathway using
PD98059 [49,50]. This suggests that under situations of
cellular distress ERK attempts to rescue the cell from
death. Numerous other micronutrients have shown cell
growth inhibition primarily through negative regulation
of the ERK pathway [51]. MEK1/2 inhibitors potentiate
apoptosis caused by Tyrphostin AG825 and a check point
abrogator UCN-01 in breast and prostate cancer cells
[18,52]. Also, ERK inhibition is able to increase radiation
induced apoptosis in DU145 cells [53-55].
There is a growing body of evidence that identify ERK as
an enzyme responsible for increased invasive and meta-
static potential in prostate cancer. Our studies in PC3 cells
demonstrate that ERK signal transduction pathway plays
only a minor role in growth and proliferation of these
cells, but is essential for clonogenic activity, cell migration
and invasion [Koul S et al in preparation]. Our studies
demonstrate that ERK signal transduction does not appear
to play a role in cell growth, but is essential for new colony
formation. This raises interesting aspects in modulation
for oncologic control. Clearly, invasion and metastasis are
the elements of tumors that make them malignant and the
cause of patient suffering. However, ERK inhibition may
not affect already developed metastatic sites. This might
lend to early use of inhibitors or modulators of this
pathway while disease burden is still low and/or possibly
as prevention of tumor metastasis.
With such a large body of evidence supporting a role for
ERK MAP kinase signal transduction pathway in promot-
ing tumorigenesis in prostate cancer, we recognize that
p42 / p44 MAP kinase signal transduction pathway may
serve as a novel target for the treatment of prostate cancer.Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/5
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C-Jun N-terminal kinase (JNK) and the prostate
Expression and activation of JNK in tissue
The presence of active JNK in normal tissues from prosta-
tectomy specimens is somewhat controversial, even in the
same research groups [1,2]. Most studies show that JNK
expression or activation is increased in neoplastic cells [3].
Additionally, JNK activity appears to be inversely related
to MKP-1 expression. An interesting sidebar to the use of
transgenic adenocarcinoma of mouse prostate (TRAMP)
mice by Uzgare et al showed that JNK expression can
increase in poorly differentiated tumors without an appar-
ent increase in activation. JNK is generally activated by cel-
lular stress, however, numerous molecules are able to
phosphorylate the enzyme [Table 3]. 2-methoxyestradiol
(ME), an endogenous metabolite of estradiol, can syner-
gize with taxol to increase JNK activation and enhance the
apoptotic effect of this chemotherapeutic agent [56]. N-
(4-hydroxyphenyl)retinamide (4-HPR) is a synthetic ana-
log of all-trans retinoic acid and has shown some promise
in localized and preventative breast cancer treatment.
Poorly differentiated androgen-insensitive PC3 cells seem
somewhat resistant to 4-HPR induced JNK phosphoryla-
tion, while androgen-sensitive LNCaP cells appear to be
quite sensitive correlating with clinical behavior in breast
cancer studies [57,58]. Numerous other agents have been
studied regarding JNK activation in prostate cancer cell
lines and these include the following: Ghosh et al showed
that inhibition of arachidonate 5-lipoxygenase (an
enzyme that converts arachidonic acid to 5-HETE) caused
rapid depletion of 5-HETE and activation of JNK, which
triggered apoptosis in LNCaP and PC3 cells [59]. This sug-
gests 5-HETE can be a critical cell cycle regulator as it acti-
vates ERK when abundant. The unique ability to activate
JNK might not only come from antioxidants. Reactive
oxygen species, in of themselves, can increase JNK in a
study with multi-cellular prostate cancer spheroids [60].
The phorbol esters are used widely to experimentally pro-
mote tumor growth and are well known for activation of
PKC. Thapsigargin is a potent inhibitor of the sarcoplam-
sic/endoplasmic reticulum calcium ATPase (SERCA)
pump, which results in rapid increase in intracellular cal-
cium ion.
Protein signaling
While JNK appears to be involved in the cross talk
between many pathways there is some research into recep-
tors that may activate JNK. In particular, the TNF-related
apoptosis inducing ligand (TRAIL) receptor can activate
JNK, although this effect is not necessary for apoptosis
caused by this receptor suggesting other pathways are acti-
vated [61,62]. Certain proteins in the cell can play a roll in
activating the JNK modular pathway. Prostate apoptosis
response (PAR) – 4 appears to supplement JNK activity as
loss of this protein caused hyperactivation of NF-kappaB
and impairment of JNK and p38 [63]. In DU145 cells nor-
mally deficient of the Retinoblastoma (Rb) gene, reactiva-
tion of this gene is required for gamma irradiation
induced JNK phosphorylation. Additionally, this study
showed that mutant jun blocked radiation induced apop-
tosis [64]. Fas also plays a role in JNK activation, as well as
STE20-like kinase and Janus kinase/signal transducer and
activator of transcription (JAK/STAT) [12,65,66]. Immedi-
ately upstream is from JNK is MKK 4 and 7 which have not
been studied in great detail with regard to prostate cancer.
However, one study showed that MKK 4 acts as one of
seven genes that are metastasis suppressers without sup-
pressing tumor growth [67]. A number of proteins nega-
tively regulate JNK. As mentioned previously,
arachidonate 5-lipoxygenase which converts arachidonic
acid to 5-HETE provides a substrate that appears to pre-
vent JNK activation [59]. Additionally, NF-kappaB activa-
tion is able to prevent JNK phosphorylation caused by 4-
HPR [49]. MAPK phosphatases have an important role in
the regulation of kinase activation. Phenylethyl isothiocy-
Table 2: p42/p44 MAP kinase inactivating agents in Prostatic cells
Endogenous
Calcitonin DU145 ? 100
15-(S)-HETE PC3 ? 38
Exogenous
Lovastatin (HMG-CoA reductase inhibitor) PC3 ? 33
Grape seed extracta DU145 ? 101,102
Methyl selenium molecules DU145 ? 27,103,104
Silibinin LNCaP, DU145 ? 105
Silymarin DU145 ? 51
Genistein DU145, AT6.3 ? 51,106
Kaempferol AT6.3 ? 106
Biochanin A AT6.3 ? 106
Quercetin PC3 ? 91
Phenylacetate LNCaP ? 34
a Can activate ERK at higher dosesCell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/5
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anate (PEITC) increases JNK activity through the inactiva-
tion of phosphatases (M3/6) in LNCaP cells [68]. Another
study showed that over expression of MKP-1 and DU145
cells blocked the activation of JNK [69]. JNK is able to acti-
vate numerous functions in the prostate cancer cell, which
include both transcription factors and functional pro-
teins. The most well known substrate for JNK is c-jun and
JNK activation is synonymous with c-jun  phosphoryla-
tion. JNK is able to activate the transcription factor AP1
[70]. JNK when activated can phosphorylate serine 62 on
Bcl-xL, which effectively prevents this protein's anti-apop-
totic effects [56]. JNK is also able to activate numerous dif-
ferent caspases including 3, 8, and 9, as well as prevent
nucleosome formation [59,71]. The specific activity of the
different isoforms is still unknown. As lab techniques
improve, undoubtedly we will have better answers. An
interesting study that examined the role of JNK2 used
serial analysis of gene expression (SAGE) in PC3 cells.
These authors found that genes involved in DNA repair,
mRNA turnover, and drug resistance were down regulated
by JNK2 inactivation [72]. This suggests a role for JNK2 in
cell saving. Also multiple MAPKs including JNK appear to
play a role in the upregulation of the urokinase-like plas-
minogen activator (U-PA) promoter in PC 3 cells [73].
Regarding gross cellular function in the cell, authors have
shown that activation of JNK regulates the cytoskeleton;
prevention of nucleosome formation and mitochondrial
dysfunction appear to also be major events following JNK
activation [59,66,69]. JNK appears to be overwhelmingly
involved in apoptotic pathways shown by multiple stud-
ies using a variety of molecules, protein and hormones to
activate JNK. JNK activation has been shown to be a cru-
cial step in the apoptosis induced by nonsteroidal anti-
inflammatory drugs in human colon cancer cells [74].
Hypoxia appears to be another condition in which JNK is
phosphorylated. This was shown in male rats that were
castrated and subsequently had the environment of the
ventral prostate gland examined [75].
Results of JNK activation
JNK activation is not a necessity for apoptosis as demon-
strated in multiple studies using inhibitors or dominant
negative cell lines. Despite overwhelming studies suggest-
ing JNK activation and apoptosis, several well-performed
studies suggest that JNK inactivation is beneficial. Differ-
ent roles for JNK1 and JNK2 are of interest and poorly
understood. As mentioned previously, JNK2 inactivation
prevented the up regulation of genes involved in DNA
repair, mRNA turnover and drug resistance [72]. Other
studies using anti-sense forms of JNK have revealed some
interesting findings. One study has suggested that JNK is
more active in growth and proliferation [76]. These
authors exposed human prostate cancer lines to anti-sense
JNK1 and JNK2 and found that anti-sense JNK1 inhibited
growth and anti-sense JNK2 inhibited proliferation. This
study suggests that JNK is a potential target for prostate
cancer growth. Another study reviewed the methods for
sensitizing prostate cancer cells to cisplatin, by expression
of p53 and anti-sense JNK [77].
p38 MAP kinase MAP kinase (p38) and the prostate
In non-cancerous human prostate tissue p38 MAP kinase
protein is present in the basal cells and epithelial cells of
the prostate gland, but one study has shown it to be
absent in the epithelial layer [2]. While likely present it is
not normally activated in epithelial tissue samples that
have been studied, but has stronger activity in the pros-
tatic stroma similar to ERK. However, epithelial p38 MAP
kinase can become active in situations of neoplasia and
benign hypertrophy of the prostate gland [3]. One study
using TRAMP mice suggested that the strong epithelial
p38 MAP kinase activation present in intraepithelial neo-
plasia and well-differentiated tumors but might be lost in
poorly differentiated tumors [78]. Similar to JNK, p38
MAP kinase is a kinase primarily activated by external
stresses. Table 4 describes a number of other activators.
Many growth and endocrine factors are able to activate
p38 MAP kinase including FGF-1 and -2, keratinocyte-
derived growth factor (KGF), IL-6, heparin binding epi-
dermal growth factor (HB-EGF), ATP, vitamin D, and Neu
differentiation factor (NDF) [13,25,47,79-81]. This acti-
vation has been demonstrated in both DU145 and LNCaP
cells. However, PC3 cells are conspicuously absent from
studies involving p38 MAP kinase activation, at least in
regards to the response to growth and endocrine factors.
Response of p38 MAP kinase to these various hormones
can range in time from several minutes to several hours,
which suggests indirect inducible activation of this MAPK.
Intracellular signaling prior to the p38 MAP kinase mod-
ule appears to be complex and incompletely described.
Protein kinase C is able to activate p38 MAP kinase,
although perhaps indirectly [82]. PAR4 loss causes
impairment of p38 MAP kinase phosphorylation[63]. The
JAK/STAT family of proteins also appears to be able to
activate p38 MAP kinase [12]. The particular roles of the
immediate upstream activator of p38 MAP kinase,
MAPKK 3/6, have not been studied extensively in the
prostate literature. The immediate downstream proteins
and transcription factors of p38 MAP kinase are still in the
process of being defined, and have not been studied in
prostate. p38 MAP kinase is well known to activate the
transcription factor NF-Kappa B [83]. p38 MAP kinase
also appears to have some role in activating caspases [84].
p38 is also able to increase the expression of certain pro-
teins including chromium induced HIF-1α expression, up
regulation of the U-PA promoter in PC3 cells, and PSA
induced by IL-6 in LNCaP cells [73,85,86]. P38 inhibition
was able to decrease the activation of actin stress fibers in
DU145 cells [79,87]. This appears to be largely a roleCell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/5
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induced by growth factors. Another study demonstrated
neuroendocrine differentiation in LNCaP cells via a p38
MAP kinase dependent mechanism [80]. Some authors
have postulated the determination of the p-ERK to p-p38
MAP kinase ratio might be able to predict the in vivo
behavior of cancer, including the prostate [88]. Cellular
death appears to be the overwhelming effect of cells with
active p38 MAP kinase. Again as in the case with other sig-
nals, p38 MAP kinase is not requisite for cellular apopto-
sis and clearly the balance of p38 MAP kinase activation
versus other signals probably determines cellular out-
come. Our studies demonstrated that inhibition of p38
MAP kinase pathway resulted in inhibition of the DNA
synthesis and growth and proliferation of PC3 cells. [Koul
et al In preparation]. Additional studies in our laboratory
are currently underway in to further evaluate function of
p38 MAP kinase signaling pathway in other prostate can-
cer cell lines.
Conclusions and future directions
MAPK signal transduction pathways seem to play diverse
role in prostate physiology. Significant differences have
been observed in the activation pattern of all three major
MAPK families (ERK, JNK and p38 MAPK) in prostate epi-
thelial and stromal cells and under normal and patho-
physiological conditions. Modulation of these MAP
Table 3: JNK stimulating agents in prostatic cells
Agent Cell line Apoptosis Ref
NDF/Heregulin LNCaP ? 81
TGF-b DU145, PC3 ? 107,108
2-methoxyestradiol (2-ME) LNCaP, PC3, Dunning Rat Model Suggested 109
N-(4-hydroxyphenyl)retinamide (4-HPR) LNCaP + 49,50,57
Anisomycin (translation inhibitor) DU145, PC3 + 62,71
Cryptophycin-52 (antimicrotubule agent) LNCaP, DU145 + 110
Tumor necrosis factor (TNF) LNCaP (mild), DU145 ? 70
Grape seed extract DU145 + 102
Selenite DU145 ? 104
Zinc DU145, PC3 ? 111
Methionine restriction PC3 + 112
Phorbol esters LNCaP ? 113
Thapsigargin LNCaP ? 113
Arsenic trioxide DU145, PC3 - 114
PEITC LNCaP + 68
Table 4: p38 MAP kinase activating agents in prostatic cells
Agent Cell line Apoptosis Ref
FGF-1 DU145 ? 79
FGF-2 DU145 ? 79
Keratinocyte growth factor (FGF-
7)
DU145 ? 79
IL-6 LNCaP ? 13
TGF-β PC3 + 87
Adenosine triphosphate 1E8, 2B4 ? 25
Neu differentiation factor (NDF)/
Heregulin
LNCaP ? 81
Vitamin D LNCaP ? 47
Selenite DU145 ? 104
Arsenic trioxide DU145, PC3 - 114
PEITC PC3 - 46
Tyrphostin AGE82 LNCaP + 18
FTY720 DU145 - 84
Phorbol esters LNCaP + 82Cell Communication and Signaling 2004, 2 http://www.biosignaling.com/content/2/1/5
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kinase pathways has also been demonstrated in various
prostate cancer cell lines by growth factors, cytokines and
variety of agents that modulate growth and apoptosis of
these cells. However, structure and function of MAP
kinase signal transduction pathways have not been
defined in sufficient detail in prostate gland under normal
conditions and under the pathologic conditions like
benign hyperplasia and prostate cancer. Moreover, pros-
tate is a heterogeneous gland, comprising of several cell
types each cell type regulating the function of the other
cell type by para-crine mechanisms, it is important to
understand the role played by MAP kinase signal trans-
duction pathways in mediating communication between
various neighboring cell types in the prostate. Despite
these limitations, ample circumstantial evidence suggests
an important role for MAP kinase signal transduction
pathways in prostate physiology and pathophysiology.
Thus additional studies are warranted to study the struc-
ture of MAP kinase pathways in prostate epithelial cells
under normal and pathophysiological conditions of BPH
and PCa. In addition, we know a divergent array of sign-
aling cascades can serve as activating elements upstream
of the core MAPK modules [Fig 1]. Identification of the
signaling cascades that are selectively activated in normal
prostate and in hormone responsive and hormone refrac-
tory prostate cancer cells is critical in identification of
selective targets and development of new and rational
therapies for treatment of prostate cancer.
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